Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities

Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage. Given price differentials between CAB‐LA and TDF/FTC, evaluating the cost‐effectiven...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2026-01-01
Serie:	Journal of the International AIDS Society
Soggetti:	cabotegravir cost‐effectiveness analysis emtricitabine tenofovir disoproxil fumarate drug combination HIV prevention men who have sex with men PrEP
Accesso online:	https://doi.org/10.1002/jia2.70061
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!